{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T04:34:42Z","timestamp":1722227682837},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,5,2]],"date-time":"2011-05-02T00:00:00Z","timestamp":1304294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s00210-011-0629-7","type":"journal-article","created":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T14:32:45Z","timestamp":1304260365000},"page":"627-633","source":"Crossref","is-referenced-by-count":10,"title":["Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson\u2019s disease"],"prefix":"10.1007","volume":"383","author":[{"given":"Thomas","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Woitalla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegfried","family":"Muhlack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,2]]},"reference":[{"key":"629_CR1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jnnp.58.3.293","volume":"58","author":"Y Ben Shlomo","year":"1995","unstructured":"Ben Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58:293\u2013299","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"629_CR2","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/phrs.1997.0145","volume":"35","author":"P Benetello","year":"1997","unstructured":"Benetello P, Furlanut M, Fortunato M, Pea F, Baraldo M (1997) Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association. Pharmacol Res 35:313\u2013315","journal-title":"Pharmacol Res"},{"key":"629_CR3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12017-007-8006-x","volume":"9","author":"D Caccamo","year":"2007","unstructured":"Caccamo D, Gorgone G, Curro M, Parisi G, Di IW, Menichetti C, Belcastro V, Parnetti L, Rossi A, Pisani F, Ientile R, Calabresi P (2007) Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Neuromolecular Med 9:249\u2013254","journal-title":"Neuromolecular Med"},{"key":"629_CR4","author":"F Cacciapuoti","year":"2011","unstructured":"Cacciapuoti F (2011) Hyper-homocysteinemia: a novel risk factor or a powerful marker for cardiovascular diseases? Pathogenetic and therapeutical uncertainties. J Thromb Thrombolysis. doi: 10.1007\/s11239-011-0550-4","journal-title":"J Thromb Thrombolysis"},{"key":"629_CR5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00228-009-0622-y","volume":"65","author":"M Kuoppamaki","year":"2009","unstructured":"Kuoppamaki M, Korpela K, Marttila R, Kaasinen V, Hartikainen P, Lyytinen J, Kaakkola S, Hanninen J, Loyttyniemi E, Kailajarvi M, Ruokoniemi P, Ellmen J (2009) Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa\/carbidopa\/entacapone and levodopa\/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 65:443\u2013455","journal-title":"Eur J Clin Pharmacol"},{"key":"629_CR6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/mds.20261","volume":"20","author":"P Lamberti","year":"2005","unstructured":"Lamberti P, Zoccolella S, Iliceto G, Armenise E, Fraddosio A, de Mari M, Livrea P (2005) Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson\u2019s disease patients. Mov Disord 20:69\u201372","journal-title":"Mov Disord"},{"key":"629_CR7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00002826-199702000-00007","volume":"20","author":"JW Miller","year":"1997","unstructured":"Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA (1997) Effect of Levodopa and the catechol-O-methyltransferase inhibitor Ro 41\u20130960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 20:55\u201366","journal-title":"Clin Neuropharmacol"},{"key":"629_CR8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/B978-0-12-381326-8.00004-1","volume":"95","author":"T Muller","year":"2010","unstructured":"Muller T (2010a) Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-L-methionine and related mechanisms. Int Rev Neurobiol 95:49\u201371","journal-title":"Int Rev Neurobiol"},{"key":"629_CR9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4137\/CMT.S1169","volume":"2","author":"T Muller","year":"2010","unstructured":"Muller T (2010b) The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson\u2019s disease. Clinical Medicine Insights: Therapeutics 2:155\u2013168","journal-title":"Clinical Medicine Insights: Therapeutics"},{"key":"629_CR10","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00228-006-0132-0","volume":"62","author":"T Muller","year":"2006","unstructured":"Muller T, Kuhn W (2006) Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson\u2019s disease patients. Eur J Clin Pharmacol 62:447\u2013450","journal-title":"Eur J Clin Pharmacol"},{"key":"629_CR11","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/mds.22607","volume":"24","author":"T Muller","year":"2009","unstructured":"Muller T, Kuhn W (2009) Homocysteine levels after acute levodopa intake in patients with Parkinson\u2019s disease. Mov Disord 24:1339\u20131343","journal-title":"Mov Disord"},{"key":"629_CR12","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1007\/s00702-009-0275-0","volume":"116","author":"T Muller","year":"2009","unstructured":"Muller T, Muhlack S (2009) Peripheral COMT inhibition prevents levodopa associated homocysteine increase. J Neural Transm 116:1253\u20131256","journal-title":"J Neural Transm"},{"key":"629_CR13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.parkreldis.2010.07.012","volume":"16","author":"T Muller","year":"2010","unstructured":"Muller T, Muhlack S (2010) Acute homocysteine rise after repeated levodopa application in patients with Parkinson\u2019s disease. Parkinsonism Relat Disord 16:688\u2013689","journal-title":"Parkinsonism Relat Disord"},{"key":"629_CR14","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00702-006-0442-5","volume":"113","author":"T Muller","year":"2006","unstructured":"Muller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D (2006) Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa\/carbidopa with and without entacapone in patients with Parkinson\u2019s disease. J Neural Transm 113:1441\u20131448","journal-title":"J Neural Transm"},{"key":"629_CR15","author":"T Muller","year":"2011","unstructured":"Muller T, Jugel C, Ehret R, Ebersbach G, Bengel G, Muhlack S, Klostermann F (2011) Elevation of total homocysteine levels in patients with Parkinson\u2019s disease treated with duodenal levodopa\/carbidopa gel. J Neural Transm. doi: 10.1007\/s00702-011-0614-9","journal-title":"J Neural Transm"},{"key":"629_CR16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(02)00353-2","volume":"207","author":"K Nakaso","year":"2003","unstructured":"Nakaso K, Yasui K, Kowa H, Kusumi M, Ueda K, Yoshimoto Y, Takeshima T, Sasaki K, Nakashima K (2003) Hypertrophy of IMC of carotid artery in Parkinson\u2019s disease is associated with levodopa, homocysteine, and MTHFR genotype. J Neurol Sci 207:19\u201323","journal-title":"J Neurol Sci"},{"key":"629_CR17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10072-010-0262-0","volume":"31","author":"M Nevrly","year":"2010","unstructured":"Nevrly M, Kanovsky P, Vranova H, Langova K, Hlustik P (2010) Effect of entacapone on plasma homocysteine levels in Parkinson\u2019s disease patients. Neurol Sci 31:565\u2013569","journal-title":"Neurol Sci"},{"key":"629_CR18","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s00702-004-0262-4","volume":"112","author":"E Nissinen","year":"2005","unstructured":"Nissinen E, Nissinen H, Larjonmaa H, Vaananen A, Helkamaa T, Reenila I, Rauhala P (2005) The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats. J Neural Transm 112:1213\u20131221","journal-title":"J Neural Transm"},{"key":"629_CR19","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1212\/01.wnl.0000219815.83681.f7","volume":"66","author":"RB Postuma","year":"2006","unstructured":"Postuma RB, Espay AJ, Zadikoff C, Suchowersky O, Martin WR, Lafontaine AL, Ranawaya R, Camicioli R, Lang AE (2006) Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 66:1941\u20131943","journal-title":"Neurology"},{"key":"629_CR20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.parkreldis.2005.01.007","volume":"11","author":"P Valkovic","year":"2005","unstructured":"Valkovic P, Benetin J, Blazicek P, Valkovicova L, Gmitterova K, Kukumberg P (2005) Reduced plasma homocysteine levels in levodopa\/entacapone treated Parkinson patients. Parkinsonism Relat Disord 11:253\u2013256","journal-title":"Parkinsonism Relat Disord"},{"key":"629_CR21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/01.WNF.0000220817.94102.95","volume":"29","author":"TA Zesiewicz","year":"2006","unstructured":"Zesiewicz TA, Wecker L, Sullivan KL, Merlin LR, Hauser RA (2006) The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clin Neuropharmacol 29:106\u2013111","journal-title":"Clin Neuropharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-011-0629-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-011-0629-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-011-0629-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T16:14:54Z","timestamp":1558628094000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-011-0629-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,2]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1007\/s00210-011-0629-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,2]]}}}